The short version of acylated peptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-02. Anything still debated is marked as such rather than presented as settled.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Acylated GLP-1 receptor agonist | 31-residue synthetic peptide |
| Molecular formula | C187H291N45O59 | established for the free peptide |
| Appearance | White to off-white powder | as supplied before formulation |
| Solubility | Freely soluble in water | aqueous buffers near neutral pH |
| Typical storage | 2 to 8 degrees Celsius, protected from light | powder and solution forms differ in shelf life |
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
== Use during the 20th century == During the 20th century its use declined as governments regulated its ingredients (opium is a controlled substance in many countries). Beginning in late 2011, there was a period in which paregoric was not being manufactured in the United States. As of August 2012, however, the manufacture of paregoric had resumed.
After Protestantism, individuals professing no religion are also a significant group, having exceeded 8% of the population according to the 2010 census. The cities of Boa Vista, Salvador, and Porto Velho have the greatest proportion of Irreligious residents in Brazil. Teresina, Fortaleza, and Florianópolis were the most Roman Catholic in the country. Greater Rio de Janeiro, not including the city proper, is the most irreligious and least Roman Catholic Brazilian periphery, while Greater Porto Alegre and Greater Fortaleza are on the opposite sides of the lists, respectively. In October 2009, the Brazilian Senate approved, and enacted by the President of Brazil in February 2010, an agreement with the Vatican, in which the Legal Statute of the Catholic Church in Brazil is recognized.
With a decreasing number of mothers who breast-feed, more infants become obese children as they grow up and are reared on infant formula instead. Fewer children go outside and engage in active play as technology, such as television and video games, keeps children indoors. Rather than walking or biking to a bus-stop or directly to school, more school-age children are driven to school by their parents, reducing physical activity. As family sizes decrease, the children's pester power, their ability to force adults to do what they want, increases. This ability enables them to have easier access to calorie-packed foods, such as candy and soda drinks. The social context around family meal-time plays a role in rates of childhood obesity.
Sources: en.wikipedia.org
=== Skin === The rheumatoid nodule, which is sometimes in the skin, is the most common non-joint feature and occurs in 30% of people who have RA. It is a type of inflammatory reaction known as a "necrotizing granuloma". The initial pathologic process in nodule formation is unknown but may be essentially the same as the synovitis, since similar structural features occur in both. The nodule has a central area of fibrinoid necrosis that may be fissured and which corresponds to the fibrin-rich necrotic material found in and around an affected synovial space. Surrounding the necrosis is a layer of palisading macrophages and fibroblasts, corresponding to the intimal layer in synovium and a cuff of connective tissue containing clusters of lymphocytes and plasma cells, corresponding to the subintimal zone in synovitis. The typical rheumatoid nodule may be a few millimetres to a few centimetres in diameter and is usually found over bony prominences, such as the elbow, the heel, the knuckles, or other areas that sustain repeated mechanical stress. Nodules are associated with a positive RF (rheumatoid factor) titer, ACPA, and severe erosive arthritis. Rarely, these can occur in internal organs or at diverse sites on the body. Several forms of vasculitis occur in RA, but are mostly seen with long-standing and untreated disease. The most common presentation is due to involvement of small- and medium-sized vessels. Rheumatoid vasculitis can thus commonly present with skin ulceration and vasculitic nerve infarction known as mononeuritis multiplex.
=== Chronic toxicity === Ingestion of melamine may lead to reproductive damage, or bladder or kidney stones, which can lead to bladder cancer. A study in 1953 reported that dogs fed 3% melamine for a year had the following changes in their urine: (1) reduced specific gravity, (2) increased output, (3) melamine crystalluria, and (4) protein and occult blood. A survey commissioned by the American Association of Veterinary Laboratory Diagnosticians suggested that crystals formed in the kidneys when melamine combined with cyanuric acid, "don't dissolve easily. They go away slowly, if at all, so there is the potential for chronic toxicity."
Entrepreneur of the Year, Recipient 1981 (Awarded by the Research Directors' Association of Chicago) Entrepreneur of the Year, Recipient 1983 (Awarded by Stanford Business School Alumni Association, Peninsula Chapter) Golden Plate Award of the American Academy of Achievement, Recipient 1986 Distinguished Entrepreneur of the Year, Recipient 1993 (Awarded by Babson College) Exemplary Leadership in Management Award, Recipient 1997 (Anderson School of Business) National Medal of Technology, Recipient 1999 Biotechnology Heritage Medal, Recipient 2000 (Posthumously Awarded by the Biotechnology Industry Organization and the Chemical Heritage Foundation) Royal Swedish Academy of Engineering Sciences, Appointed Member
== Mechanism of action == Avanafil inhibits phosphodiesterase-5, preventing the degradation of cGMP. The increased levels of cGMP causes vasodilation, resulting in an increased blood flow in the penis. Avanafil's mechanism of action takes place once nitric oxide is released, in association with sexual stimulation.
Sources: en.wikipedia.org
Lemna Ecotox testing Duckweed growth inhibition tests and standardisation OECD Guideline for Lemna Test Archived 2016-01-07 at the Wayback Machine USDA Plants Profile: North American Species Jepson Manual Treatment: Lemna
In 1981 Channon left Guy's Hospital to continue his work with Drs Martin Hartog and Richard Paisey at the Bristol Royal Infirmary. Channon then developed the miniature Portaject device. Unlike the Multiject the Portaject is designed to be worn. It has the capacity for sufficient insulin for 24 hours (at the time insulin had to be refrigerated; at room or body temperature it would become unusable after 24 hours). Channon self-funded the design and fabrication work through his company Channon Medical Ltd. He filed a patent for the Portaject in 1988 but subsequently withdrew the application, choosing instead to donate his research to the field. Clinical trials at the BRI were supported by a small grant of £4,500 from the National Medical Research fund. Dr Hartog attests that "Portaject was the first device that allowed convenient repeated subcutaneous injections of insulin and led to the Novopen. Administration of insulin in this way resulted in a much improved control of the patient's diabetes and, consequently, to a considerably improved prognosis overall". Dr Paisey recalls that clinical trials were conducted with 20 patients and that "one of them continued for 20 years with the same device and achieved good glycemic control. He also designed and manufactured a belt to house the pump". Another long term user, Stephen Dixon, wrote to Channon "Thanks so much for doing what you did. You truly helped transform millions of lives, including mine". In 1989 Channon developed a simple device for protecting, lubricating and sterilizing a hypodermic needle.
"Le minutier central des notaires de Paris aux Archives nationales" [The central minute book of Paris notaries at the National Archives] (in French). Archived from the original on May 28, 2013. "Base Léonore, le fonds de la Légion d'honneur aux Archives nationales" [Base Léonore, the Legion of Honor collection at the French National Archives] (in French). Archived from the original on May 14, 2013. Dictionnaire critique de biographie et d'histoire [Critical Dictionary of Biography and History] (in French). 1872. Archived from the original on July 21, 2015. (where the author, Auguste Jal, transcribed numerous birth, baptism, marriage, death and burial certificates of historical and famous personalities before they were destroyed in 1871). Notes prises aux archives de l'état-civil de Paris [Notes taken from the Paris registry office archives] (in French). 1875. Archived from the original on January 1, 2022. Piot, Eugène (1873). "État civil de quelques artistes français" [Marital status of some French artists] (in French). Paris Pagnerre. "Projet Familles Parisiennes" [Parisian Families Project] (in French). Archived from the original on January 1, 2022. "La vie des Parisiens du XIXe siècle se met à revivre !" [Nineteenth-century Parisians come to life!] (in French). Archived from the original on January 18, 2022. Vanwelkenhuyzen, Michel.
An allosteric site is a site on an enzyme, unrelated to its active site, which can bind an effector molecule. This interaction is another mechanism of enzyme regulation. Allosteric modification usually happens in proteins with more than one subunit. Allosteric interactions are often present in metabolic pathways and are beneficial in that they allow one step of a reaction to regulate another step. They allow an enzyme to have a range of molecular interactions, other than the highly specific active site.
In budding yeast, 14/78 ribosomal proteins are non-essential for growth, while in humans this depends on the cell of study. Other forms of heterogeneity include post-translational modifications to ribosomal proteins such as acetylation, methylation, and phosphorylation. Arabidopsis, Viral internal ribosome entry sites (IRESs) may mediate translations by compositionally distinct ribosomes. For example, 40S ribosomal units without eS25 in yeast and mammalian cells are unable to recruit the CrPV IGR IRES. Heterogeneity of ribosomal RNA modifications plays a significant role in structural maintenance and/or function and most mRNA modifications are found in highly conserved regions. The most common rRNA modifications are pseudouridylation and 2'-O-methylation of ribose.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.
The fatty diacid chain associates strongly with serum albumin, which keeps the peptide in circulation and shields it from rapid renal clearance. Bound peptide is released gradually, producing a sustained receptor signal. This mechanism also reduces the peak-to-trough variation seen with shorter-acting analogues.
The balance between peripheral receptor activation and signalling in the central nervous system is not fully resolved. The extent to which slowed gastric emptying accounts for reduced energy intake, compared with direct effects on appetite circuits, is debated. Long-term effects on lean mass and on tissues outside the gut and brain are still under study.
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.